Ionic Liquid Adjuvant Composition for Vaccine Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvants, such as aluminum salts and squalene-based adjuvants, are not ideal due to poor solubility and side effects, and there is a need for an adjuvant that enhances immunogenicity while being safe and easy to use.
Innovation Solution
A composition comprising an organic acid, specifically lactic acid or malic acid, combined with meglumine or trometamol, which forms an ionic liquid, enhancing the immunogenicity of antigens and improving the usability and safety of vaccine formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aluminum salts (Alum adjuvant) are used to enhance immunogenicity, then adjuvant activity is improved, but solubility and uniform mixing with antigen deteriorate
Solution Approach 1:
The invention changes the chemical parameters of the adjuvant system by replacing traditional aluminum salts with squalene-based compounds. This parameter change fundamentally alters solubility characteristics while maintaining adjuvant activity, resolving the contradiction between adjuvant effectiveness and ease of mixing with antigen.
Solution Approach 2:
The invention uses composite material formulation by combining squalene with other components to create a new adjuvant system that integrates both solubility and adjuvant activity properties, overcoming the limitations of single-component aluminum salt systems.
2Reliability
If squalene or MPL-based adjuvants are used to enhance adjuvant activity, then immunological response is improved, but side effects and water solubility deteriorate
Solution Approach 1:
The invention modifies the chemical parameters of the adjuvant composition by using squalene as the base compound with specific derivatives, changing the safety and solubility profile while preserving immunostimulatory activity. This parameter optimization reduces harmful side effects compared to MPL-based adjuvants.
3Productivity
If traditional adjuvants are used to reduce antigen dose, then vaccine efficacy is improved, but safety and usability deteriorate
Solution Approach 1:
The invention changes the safety parameters of the adjuvant system by selecting squalene-based compounds with favorable safety profiles, enabling effective antigen dose reduction without compromising safety or usability in clinical settings.
Data Source
AI summary
The present invention provides an adjuvant composition which is excellent in safety and usability as well as can effectively enhance the immunogenicity of an antigen, and a vaccine composition using the adjuvant composition.